VivaCell Biotechnology — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

VivaCell Biotechnology is a Dresden-based CRO founded in 2005, providing specialized in vitro and ex vivo testing services to validate the efficacy and safety of products across pharmaceuticals, nutraceuticals, and cosmetics. The company leverages established biological assays and models to generate scientific certificates for client products. Its recent acquisition by the CDMO 1Q Health Group in 2025 positions it for enhanced service offerings and growth within a larger manufacturing and development network.

Women's Health (Menopause)ImmunologyInflammationMetabolic Disorders

Technology Platform

Specialized in vitro and ex vivo assay platforms for product validation. Features modular testing systems for specific pathways, e.g., a Menopause Research platform targeting serotonin, dopamine, adrenergic, opioid, and estrogen receptors, and related cellular functions.

Opportunities

Integration into the 1Q Health CDMO group enables offering clients a seamless service from efficacy testing to manufacturing.

Growing consumer and regulatory demand for scientifically-validated health claims in nutraceuticals and cosmetics drives demand for its specialized testing services.

Risk Factors

Faces competition in the crowded CRO market and depends on continuous client project flow.

Post-acquisition integration with 1Q Health must be managed carefully to avoid operational disruption and realize intended synergies.

Competitive Landscape

Competes with other specialized CROs and the preclinical service divisions of large CDMOs. Its differentiation lies in niche expertise (e.g., menopause research), ex vivo models, and its new position as the integrated research arm of a CDMO, offering a unique end-to-end value proposition.

More companies in Cell & Gene Therapy →More companies in Germany →